Researchers have found that 89Zr labelled recombinant human antibody targeting an extracellular domain on human and mouse PD-L1 could evaluate the PD-L1 levels in xenografts derived from non-small cell lung cancer (NSCLC) that subsequently responded to PD-L1 blockade [56]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.